Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689294 | 0.93 | APEX1 (0.45) | APEX1 | |
| SCHEMBL17277629 | 0.90 | APEX1 (0.59) | APEX1 | |
| SCHEMBL17834007 | 0.90 | APEX1 (0.59) | APEX1 | |
| SCHEMBL17689293 | 0.79 | APEX1 (0.55) | APEX1 | |
| SCHEMBL17277148 | 0.75 | APEX1 (0.57) | APEX1 | |
| SCHEMBL17689291 | 0.73 | APEX1 (0.75) | APEX1 | |
| SCHEMBL23234144 | 0.71 | EPHX2 (0.41) | — | |
| SCHEMBL198354 | 0.71 | EPHX2 (0.41) | — | |
| SCHEMBL61278 | 0.71 | EPHX2 (0.41) | — | |
| SCHEMBL23016820 | 0.71 | EPHX2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133175-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | APEXIAN PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9877936-B2 | Quinone compounds for treating Ape1 mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-9315481-B2 | Compounds and methods for treating leukemia | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160045461-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | APEXIAN PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9193700-B2 | Quinone compounds for treating Ape1 mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045461-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | NQO1, APEX1, KEAP1 | APEX1 2/4885 |
| US-20180133175-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | NQO1, APEX1, KEAP1 | APEX1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.